Compare OTTR & BLTE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OTTR | BLTE |
|---|---|---|
| Founded | 1907 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electric Utilities: Central | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.6B | 4.1B |
| IPO Year | N/A | 2022 |
| Metric | OTTR | BLTE |
|---|---|---|
| Price | $86.58 | $163.55 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $161.57 |
| AVG Volume (30 Days) | 174.0K | ★ 231.3K |
| Earning Date | 02-17-2026 | 03-16-2026 |
| Dividend Yield | ★ 2.67% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 6.62 | N/A |
| Revenue | ★ $1,299,070,000.00 | N/A |
| Revenue This Year | $0.18 | N/A |
| Revenue Next Year | $1.13 | N/A |
| P/E Ratio | $13.05 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $71.79 | $49.00 |
| 52 Week High | $90.11 | $174.78 |
| Indicator | OTTR | BLTE |
|---|---|---|
| Relative Strength Index (RSI) | 54.62 | 61.14 |
| Support Level | $85.96 | $156.52 |
| Resistance Level | $90.11 | $163.17 |
| Average True Range (ATR) | 1.89 | 8.59 |
| MACD | 0.20 | -0.44 |
| Stochastic Oscillator | 57.93 | 60.90 |
Otter Tail Corp is a U.S. energy company that operates in the electric (produces and sells electricity), manufacturing (fabricates metal components), and plastics segments (pipes for water uses). The company conducts its operations and acquires the majority of its revenue in the U.S. in the states of Minnesota, South Dakota, and North Dakota. The majority of the company's revenue is derived from the Electric segment and commercial customers, although it generates revenue from residential and industrial customers, as well.
Belite Bio Inc is a clinical-stage biopharmaceutical drug development company focused on novel therapeutics targeting untreatable eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease or STGD1, both of which progressively to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease, or NAFLD, nonalcoholic steatohepatitis, or NASH, type 2 diabetes, or T2D, and gout.